{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:28:33Z","timestamp":1787311713100,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Prophylactic donor lymphocyte infusion (DLI) starting at 6\u00a0months after T cell-depleted allogeneic stem cell transplantation (TCD-alloSCT) can introduce a graft-versus-leukemia (GvL) effects with low risk of severe graft-versus-host-disease (GvHD). We established a policy to apply low-dose early DLI at 3\u00a0months after alloSCT to prevent early relapse. This study analyzes this strategy retrospectively. Of 220 consecutive acute leukemia patients undergoing TCD-alloSCT, 83 were prospectively classified to have a high relapse risk and 43 were scheduled for early DLI. 95% of these patients received freshly harvested DLI within 2\u00a0weeks of the planned date. In patients transplanted with reduced intensity conditioning and an unrelated donor, we found an increased cumulative incidence of GvHD between 3 and 6\u00a0months after TCD-alloSCT for patients receiving DLI at 3\u00a0months compared to patients who did not receive this DLI (0.42 (95%Confidence Interval (95% CI): 0.14\u20130.70) vs 0). Treatment success was defined as being alive without relapse or need for systemic immunosuppressive GvHD treatment. The five-year treatment success in patients with acute lymphatic leukemia was comparable between high- and non-high-risk disease (0.55 (95% CI: 0.42\u20130.74) and 0.59 (95% CI: 0.42\u20130.84)). It remained lower in high-risk acute myeloid leukemia (AML) (0.29 (95% CI: 0.18\u20130.46)) than in non-high-risk AML (0.47 (95% CI: 0.42\u20130.84)) due to an increased relapse rate despite early DLI.<\/jats:p>","DOI":"10.1007\/s00277-023-05145-1","type":"journal-article","created":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T03:02:49Z","timestamp":1678158169000},"page":"1203-1213","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Feasibility, safety, and efficacy of early prophylactic donor lymphocyte infusion after T cell-depleted allogeneic stem cell transplantation in acute leukemia patients"],"prefix":"10.1007","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1196-4337","authenticated-orcid":false,"given":"Boris","family":"van der Zouwen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. A. S.","family":"Koster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. A.","family":"von dem Borne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. E. M.","family":"Oosten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. W. I.","family":"Roza-Scholten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. J. F.","family":"Snijders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"van Lammeren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"van Balen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. A. F.","family":"Marijt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Veelken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. H. F.","family":"Falkenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. C.","family":"de Wreede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. J. M.","family":"Halkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,7]]},"reference":[{"issue":"4","key":"5145_CR1","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1182\/blood-2002-12-3714","volume":"102","author":"S Suciu","year":"2003","unstructured":"Suciu S et al (2003) Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC\/GIMEMAAML-10 trial. Blood 102(4):1232\u20131240","journal-title":"Blood"},{"issue":"1","key":"5145_CR2","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/leu.2008.164","volume":"23","author":"M Mohty","year":"2009","unstructured":"Mohty M et al (2009) Reduced intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia: long term results of a \u201cdonor\u201d versus \u201cno donor\u201d comparison. Leukemia 23(1):194\u2013196","journal-title":"Leukemia"},{"issue":"11","key":"5145_CR3","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/j.bbmt.2019.08.014","volume":"25","author":"Z DeFilipp","year":"2019","unstructured":"DeFilipp Z et al (2019) Hematopoietic cell transplantation in the treatment of adult acute lymphoblastic leukemia: updated 2019 evidence-based review from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant 25(11):2113\u20132123","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"5145_CR4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1182\/blood-2015-07-604546","volume":"127","author":"JJ Cornelissen","year":"2016","unstructured":"Cornelissen JJ, Blaise D (2016) Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood 127(1):62\u201370","journal-title":"Blood"},{"issue":"9","key":"5145_CR5","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/14728222.2021.1992383","volume":"25","author":"H Choe","year":"2021","unstructured":"Choe H, Ferrara JLM (2021) New therapeutic targets and biomarkers for acute graft-versus-host disease (GVHD). Expert Opin Ther Targets 25(9):761\u2013771","journal-title":"Expert Opin Ther Targets"},{"issue":"12","key":"5145_CR6","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1182\/blood-2004-01-0200","volume":"104","author":"BL Stewart","year":"2004","unstructured":"Stewart BL et al (2004) Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood 104(12):3501\u20133506","journal-title":"Blood"},{"issue":"4","key":"5145_CR7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1053\/bbmt.2003.50026","volume":"9","author":"SJ Lee","year":"2003","unstructured":"Lee SJ, Vogelsang G, Flowers ME (2003) Chronic graft-versus-host disease. Biol Blood Marrow Transplant 9(4):215\u2013233","journal-title":"Biol Blood Marrow Transplant"},{"key":"5145_CR8","doi-asserted-by":"crossref","unstructured":"Pidala J et al (2020) Factors associated with successful discontinuation of immune suppression after allogeneic hematopoietic cell transplantation. JAMA Oncol. 6(1):e192974","DOI":"10.1001\/jamaoncol.2019.2974"},{"issue":"2","key":"5145_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41409-021-01515-3","volume":"57","author":"C Schmid","year":"2022","unstructured":"Schmid C et al (2022) Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia. Bone Marrow Transplant 57(2):215\u2013223","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"5145_CR10","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1038\/sj.bmt.1705385","volume":"37","author":"RM Barge","year":"2006","unstructured":"Barge RM et al (2006) Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath \u201cin the bag\u201d as T-cell depletion: the Leiden experience. Bone Marrow Transplant 37(12):1129\u20131134","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"5145_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1046\/j.1365-2141.2003.04228.x","volume":"121","author":"S Chakrabarti","year":"2003","unstructured":"Chakrabarti S et al (2003) T-cell depletion with Campath-1H \u201cin the bag\u201d for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival. Br J Haematol 121(1):109\u2013118","journal-title":"Br J Haematol"},{"issue":"2","key":"5145_CR12","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.bbmt.2012.09.003","volume":"19","author":"JD Goldberg","year":"2013","unstructured":"Goldberg JD et al (2013) T cell-depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease. Biol Blood Marrow Transplant 19(2):208\u2013213","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"5145_CR13","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.bbmt.2019.10.003","volume":"26","author":"J Montoro","year":"2020","unstructured":"Montoro J et al (2020) Ex vivo T cell-depleted hematopoietic stem cell transplantation for adult patients with acute myelogenous leukemia in first and second remission: long-term disease-free survival with a significantly reduced risk of graft-versus-host disease. Biol Blood Marrow Transplant 26(2):323\u2013332","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"5145_CR14","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1038\/sj.leu.2402203","volume":"15","author":"N Schaap","year":"2001","unstructured":"Schaap N et al (2001) Induction of graft-versus-leukemia to prevent relapse after partially lymphocyte-depleted allogeneic bone marrow transplantation by pre-emptive donor leukocyte infusions. Leukemia 15(9):1339\u20131346","journal-title":"Leukemia"},{"issue":"4","key":"5145_CR15","doi-asserted-by":"publisher","first-page":"751","DOI":"10.3324\/haematol.2013.089565","volume":"99","author":"M Eefting","year":"2014","unstructured":"Eefting M et al (2014) Intentional donor lymphocyte-induced limited acute graft-versus-host disease is essential for long-term survival of relapsed acute myeloid leukemia after allogeneic stem cell transplantation. Haematologica 99(4):751\u2013758","journal-title":"Haematologica"},{"issue":"10","key":"5145_CR16","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/j.molonc.2015.10.014","volume":"9","author":"JH Falkenburg","year":"2015","unstructured":"Falkenburg JH, Jedema I (2015) Allo-reactive T cells for the treatment of hematological malignancies. Mol Oncol 9(10):1894\u20131903","journal-title":"Mol Oncol"},{"key":"5145_CR17","doi-asserted-by":"crossref","unstructured":"Carreras E, Dufour C, Mohty M, Kr\u00f6ger N (eds) (2019) The EBMT Handbook: hematopoietic stem cell transplantation and cellular therapies [Internet], 7th ed. Springer,\u00a0Cham","DOI":"10.1007\/978-3-030-02278-5"},{"issue":"4","key":"5145_CR18","doi-asserted-by":"publisher","first-page":"506","DOI":"10.3324\/haematol.2015.136846","volume":"101","author":"M Eefting","year":"2016","unstructured":"Eefting M et al (2016) Multi-state analysis illustrates treatment success after stem cell transplantation for acute myeloid leukemia followed by donor lymphocyte infusion. Haematologica 101(4):506\u2013514","journal-title":"Haematologica"},{"issue":"4","key":"5145_CR19","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41409-018-0286-2","volume":"54","author":"CJ Lee","year":"2019","unstructured":"Lee CJ et al (2019) Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant 54(4):519\u2013530","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"5145_CR20","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1182\/blood.V112.11.2218.2218","volume":"112","author":"PA Von Dem Borne","year":"2008","unstructured":"Von Dem Borne PA et al (2008) The effect of donor lymphocyte infusion dose on the occurrence of severe life-threatening acute graft-versus-host disease early after reduced intensity conditioning T cell depleted stem cell transplantation. Blood 112(11):2218\u20132218","journal-title":"Blood"},{"issue":"1","key":"5145_CR21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood.2021012411","volume":"141","author":"A Biederst\u00e4dt","year":"2023","unstructured":"Biederst\u00e4dt A, Rezvani K (2023) How I treat high-risk acute myeloid leukemia using preemptive adoptive cellular immunotherapy. Blood 141(1):22\u201338","journal-title":"Blood"},{"issue":"1","key":"5145_CR22","first-page":"53","volume":"1","author":"JF Apperley","year":"1986","unstructured":"Apperley JF et al (1986) Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. Bone Marrow Transplant 1(1):53\u201366","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"5145_CR23","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/bjh.15881","volume":"186","author":"C Schneidawind","year":"2019","unstructured":"Schneidawind C et al (2019) G-CSF administration prior to donor lymphocyte apheresis promotes anti-leukaemic effects in allogeneic HCT patients. Br J Haematol 186(1):60\u201371","journal-title":"Br J Haematol"},{"issue":"9","key":"5145_CR24","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/sj.bmt.1705981","volume":"41","author":"C Lutz","year":"2008","unstructured":"Lutz C et al (2008) A pilot study of prophylactic donor lymphocyte infusions to prevent relapse in adult acute lymphoblastic leukemias after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 41(9):805\u2013812","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"5145_CR25","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1111\/trf.12428","volume":"54","author":"V Fisher","year":"2014","unstructured":"Fisher V et al (2014) Analysis of the recovery of cryopreserved and thawed CD34+ and CD3+ cells collected for hematopoietic transplantation. Transfusion 54(4):1088\u20131092","journal-title":"Transfusion"},{"issue":"10","key":"5145_CR26","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/j.jcyt.2016.06.014","volume":"18","author":"C Berens","year":"2016","unstructured":"Berens C et al (2016) Variable resistance to freezing and thawing of CD34-positive stem cells and lymphocyte subpopulations in leukapheresis products. Cytotherapy 18(10):1325\u20131331","journal-title":"Cytotherapy"},{"issue":"5","key":"5145_CR27","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/bjh.15691","volume":"184","author":"C Schmid","year":"2019","unstructured":"Schmid C et al (2019) Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the Acute Leukaemia Working Party of EBMT. Br J Haematol 184(5):782\u2013787","journal-title":"Br J Haematol"},{"issue":"1","key":"5145_CR28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.bbmt.2012.07.021","volume":"19","author":"M Liga","year":"2013","unstructured":"Liga M et al (2013) High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen. Biol Blood Marrow Transplant 19(1):75\u201381","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"5145_CR29","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.bbmt.2013.02.005","volume":"19","author":"HD Yun","year":"2013","unstructured":"Yun HD, Waller EK (2013) Finding the sweet spot for donor lymphocyte infusions. Biol Blood Marrow Transplant 19(4):507\u2013508","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5426","key":"5145_CR30","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1126\/science.285.5426.412","volume":"285","author":"WD Shlomchik","year":"1999","unstructured":"Shlomchik WD et al (1999) Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 285(5426):412\u2013415","journal-title":"Science"},{"issue":"9","key":"5145_CR31","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/j.bbmt.2012.06.017","volume":"18","author":"B van der Zouwen","year":"2012","unstructured":"van der Zouwen B et al (2012) Alloreactive effector T cells require the local formation of a proinflammatory environment to allow crosstalk and high avidity interaction with nonhematopoietic tissues to induce GVHD reactivity. Biol Blood Marrow Transplant 18(9):1353\u20131367","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"5145_CR32","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13045-017-0393-3","volume":"10","author":"X Poire","year":"2017","unstructured":"Poire X et al (2017) Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). J Hematol Oncol 10(1):20","journal-title":"J Hematol Oncol"},{"issue":"2","key":"5145_CR33","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.bbmt.2015.08.024","volume":"22","author":"MC Pasquini","year":"2016","unstructured":"Pasquini MC et al (2016) Hematopoietic cell transplantation outcomes in monosomal karyotype myeloid malignancies. Biol Blood Marrow Transplant 22(2):248\u2013257","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"5145_CR34","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.bbmt.2011.07.024","volume":"18","author":"P Armand","year":"2012","unstructured":"Armand P et al (2012) Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study. Biol Blood Marrow Transplant 18(2):280\u2013288","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"5145_CR35","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.bbmt.2017.11.025","volume":"24","author":"P Kebriaei","year":"2018","unstructured":"Kebriaei P et al (2018) Intravenous busulfan compared with total body irradiation pretransplant conditioning for adults with acute lymphoblastic leukemia. Biol Blood Marrow Transplant 24(4):726\u2013733","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"5145_CR36","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/leu.2013.253","volume":"28","author":"V Bachanova","year":"2014","unstructured":"Bachanova V et al (2014) Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease. Leukemia 28(3):658\u2013665","journal-title":"Leukemia"},{"key":"5145_CR37","unstructured":"Bejanyan N et al (2021) Myeloablative conditioning for allogeneic transplantation results in superior disease-free survival for acute myelogenous leukemia and myelodysplastic syndromes with low\/intermediate but not high disease risk index: a center for international blood and marrow transplant research study. Transplant Cell Ther. 27(1):68.e1-68.e9"},{"issue":"1","key":"5145_CR38","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13045-019-0790-x","volume":"12","author":"J Pavlu","year":"2019","unstructured":"Pavlu J et al (2019) Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT. J Hematol Oncol 12(1):108","journal-title":"J Hematol Oncol"},{"issue":"1","key":"5145_CR39","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1056\/NEJM199907013410103","volume":"341","author":"G Socie","year":"1999","unstructured":"Socie G et al (1999) Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med 341(1):14\u201321","journal-title":"N Engl J Med"},{"issue":"7","key":"5145_CR40","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/j.bbmt.2017.02.022","volume":"23","author":"SR Solomon","year":"2017","unstructured":"Solomon SR et al (2017) Current graft-versus-host disease-free, relapse-free survival: a dynamic endpoint to better define efficacy after allogenic transplant. Biol Blood Marrow Transplant 23(7):1208\u20131214","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"5145_CR41","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1016\/j.bbmt.2019.05.015","volume":"25","author":"SG Holtan","year":"2019","unstructured":"Holtan SG et al (2019) Dynamic graft-versus-host disease-free, relapse-free survival: multistate modeling of the morbidity and mortality of allotransplantation. Biol Blood Marrow Transplant 25(9):1884\u20131889","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"5145_CR42","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.bbmt.2020.01.001","volume":"26","author":"T Bluhmki","year":"2020","unstructured":"Bluhmki T et al (2020) Relapse- and immunosuppression-free survival after hematopoietic stem cell transplantation: how can we assess treatment success for complex time-to-event endpoints? Biol Blood Marrow Transplant 26(5):992\u2013997","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"5145_CR43","doi-asserted-by":"publisher","first-page":"839.e1","DOI":"10.1016\/j.jtct.2021.06.029","volume":"27","author":"T Guillaume","year":"2021","unstructured":"Guillaume T et al (2021) Prophylactic or preemptive low-dose azacitidine and donor lymphocyte infusion to prevent disease relapse following allogeneic transplantation in patients with high-risk acute myelogenous leukemia or myelodysplastic syndrome. Transplant Cell Ther 27(10):839.e1-839.e6","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"5145_CR44","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s00277-020-04321-x","volume":"100","author":"E Schuler","year":"2021","unstructured":"Schuler E et al (2021) Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group. Ann Hematol 100(4):959\u2013968","journal-title":"Ann Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05145-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05145-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05145-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T03:15:02Z","timestamp":1681355702000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05145-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,7]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["5145"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05145-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,7]]},"assertion":[{"value":"7 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the LUMC Ethics Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Eva Koster has a Landkroon fellowship sponsored by the Doelfonds Leukemie of the Bontius Stichting.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}